

RESEARCH ARTICLE

Synthesis and biological evaluation of dihydropyrano-[2,3-c]pyrazoles as a new class of PPAR γ partial agonists

Katrine Qvortrup¹, Jakob F. Jensen¹, Mikael S. Sørensen², Irene Kouskoumvekaki², Rasmus K. Petersen³, Olivier Taboureau^{2,4}, Karsten Kristiansen³, Thomas E. Nielsen^{1,5*}

1 Department of Chemistry, Technical University of Denmark, Lyngby, Denmark, **2** Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark, **3** Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, Copenhagen, Denmark, **4** Molécules Thérapeutiques in silico (MTi), Inserm UMR-S 973—Université Paris Diderot, Bat Lamarck A, 35 Rue Hélène Brion, Paris, France, **5** Singapore Centre on Environmental Life Sciences Engineering, Nanyang Technological University, Singapore, Singapore

* ten@sund.ku.dk



OPEN ACCESS

Citation: Qvortrup K, Jensen JF, Sørensen MS, Kouskoumvekaki I, Petersen RK, Taboureau O, et al. (2017) Synthesis and biological evaluation of dihydropyrano-[2,3-c]pyrazoles as a new class of PPAR γ partial agonists. PLoS ONE 12(2): e0162642. doi:10.1371/journal.pone.0162642

Editor: Andrea Cavalli, Università degli Studi di Bologna, ITALY

Received: March 31, 2016

Accepted: August 25, 2016

Published: February 28, 2017

Copyright: © 2017 Qvortrup et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information file.

Funding: We thank the Danish Council for Independent Research, Natural Sciences, Technology and Production Sciences, DSF Center for Antimicrobial Research, Lundbeck Foundation, and Technical University of Denmark for financial support.

Competing interests: The authors have declared that no competing interests exist.

Abstract

Peroxisome proliferator-activated receptor γ (PPAR γ) is a well-known target for thiazolidinedione antidiabetic drugs. In this paper, we present the synthesis and biological evaluation of a series of dihydropyrano[2,3-c]pyrazole derivatives as a novel family of PPAR γ partial agonists. Two analogues were found to display high affinity for PPAR γ with potencies in the micro molar range. Both of these hits were selective against PPAR γ , since no activity was measured when tested against PPAR α , PPAR δ and RXR α . In addition, a novel modelling approach based on multiple individual flexible alignments was developed for the identification of ligand binding interactions in PPAR γ . In combination with cell-based transactivation experiments, the flexible alignment model provides an excellent analytical tool to evaluate and visualize the effect of ligand chemical structure with respect to receptor binding mode and biological activity.

Introduction

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors of the nuclear hormone receptor superfamily [1]. Many cellular and systemic roles have been attributed to these receptors, reaching far beyond the stimulation of peroxisome proliferation in rodents after which they were initially named. The three PPAR subtypes PPAR α , PPAR δ and PPAR γ exhibit broad, subtype-specific tissue expression patterns. The PPAR γ subtype is most highly expressed in adipose tissue, and agonists for this receptor, increase adipocyte differentiation, enhance insulin sensitivity and improve lipid profiles [2,3]. A variety of synthetic agonists for PPAR γ have been studied in the area of antidiabetic drug discovery (Fig 1), such as the full agonists thiazolidinediones (TZDs), including rosiglitazone (1) and pioglitazone (2). These drugs are now well established in clinical practice for the treatment of type II diabetes. However, despite their effectiveness in lowering blood glucose levels and improving insulin




Fig 1. Pharmacologically relevant PPAR γ ligands.

doi:10.1371/journal.pone.0162642.g001

sensitivity [4], they have recently been associated with severe side effects, such as fluid retention, weight gain, cardiac hypertrophy, and hepatotoxicity [5,6]. Strong evidence suggest that these side-effects may be associated with full agonism, and much recent focus has been given to the development of partial agonists, which are expected to retain full insulin sensitizing effects with minimal side-effects [5,6]. One such partial agonist, balaglitazone (3), was shown to activate PPAR γ and improve glucose levels without causing undesirable accumulation of fluid and fat [7].

In view of these developments, the discovery of novel selective PPAR γ agonists with partial binding properties would be advantageous not only as candidates for the treatment of type II diabetes, but also as chemical probes to investigate the function of PPAR γ , as new roles for it are currently being identified, e.g. as anti-obesity drug target [8].

Recently, we reported [9] an integrated *in silico* / *in vitro* workflow, based on pharmacophore- and structure-based virtual screening of the ZINC library, coupled with competitive binding and transactivation assays, and adipocyte differentiation and gene expression studies. In this study, dihydropyrano[2,3-c]pyrazole 4 was identified as a promising PPAR γ partial agonist combining high inhibitor activity ($IC_{50} = 0.03$ mM) with a relatively poor induction of adipocyte differentiation. This promoted us to further investigate the dihydropyrano[2,3-c]pyrazoles as a novel class of PPAR γ ligands. Herein, we present the development of a synthetically tractable scale-up synthesis of dihydropyrano[2,3-c]pyrazole 4 for further biological studies. Furthermore, we describe the synthesis and biological evaluation of a series of novel dihydropyrano[2,3-c]pyrazole derivatives with high structural variation.

Results and discussion

1. Chemistry

1.1 Dihydropyrano[2,3-c]pyrazoles. Dihydropyrano[2,3-c]pyrazoles constitute an important class of compounds with a wide range of biological properties, such as anticancer [10], antimicrobial [11] and anti-inflammatory [12] activities. Only recently, we published data that identified the dihydropyrano[2,3-c]pyrazole 4 as a promising PPAR γ partial agonist for the treatment of type II diabetes.

The most common and convenient approach towards diverse dihydropyrano[2,3-c]pyrazoles is a two-step procedure (Fig 2) comprising the following steps: (1) Condensation of




Fig 2. Reaction pathway for the synthesis of dihydropyrano[2,3-*c*]pyrazole derivatives 10.

doi:10.1371/journal.pone.0162642.g002

hydrazine derivative **5** is condensed with β -keto ester **6** under basic conditions to produce the 1*H*-pyrazol-5(4*H*)-one derivative **7**; (2) Three-component base-catalyzed reaction of 1*H*-pyrazol-5(4*H*)-one **7**, aromatic aldehyde **8** and malononitrile **9**. The three-component reaction involve a tandem Michael addition-Thorpe-Ziegler-type reaction, followed by tautomerization [13] to generate the dihydropyrano[2,3-*c*]pyrazole core **10**. It should be noted that these compounds may exist in the 1,4-dihydro or 2,4-dihydro tautomeric forms when the N1 position is unsubstituted ($R^1 = H$).

The presented protocol represents a synthetically tractable strategy for drug discovery as the target molecule is synthesized in two high-yielding steps without the need for time-consuming chromatography. Furthermore, the general two-step sequence (Fig 2) is easily amenable to the preparation of combinatorial libraries of diverse dihydropyrano[2,3-*c*]pyrazoles. Given the large number of commercially available aldehydes and the easy access to hydrazines and β -keto esters, this method provides access to dihydropyrano[2,3-*c*]pyrazole libraries with high appendage diversity introduced through substituents at the 1-, 3-, and 4-positions.

1.2 Scale-up synthesis of lead compound 4. Dihydropyrano[2,3-*c*]pyrazole **4** is a promising PPAR γ partial agonist, that may serve as an entry for the development of new antidiabetics. We initiated our studies by developing a practical and gram-scale synthesis of **4** for compound validation, further medicinal chemistry evaluation, and lead optimization studies.

Considering the synthetic strategy outlined in Fig 2, aldehyde building block **15** constitutes a key intermediate for the scale-up synthesis of **4**. The readily available bromomethylbenzaldehyde **14** was identified as the most readily available precursor to aldehyde **15**. Our stepwise synthesis of **14** commenced with *m*-xylene, which was bis-chloromethylated to afford 1,5-bis(chloromethyl)-2,4-dimethylbenzene **12** [14]. This was then converted to dialdehyde **13** in a Sommelet reaction, following a procedure developed by Wood [15]. Selective reduction of one of the aldehyde moieties with NaBH₄ and subsequent treatment of the resulting monoalcohol with HBr in boiling AcOH afforded the bromomethylbenzaldehyde **14** [16]. Compound **14** was quantitatively converted to aldehyde **15** by reaction with 4-chloro-2-methylphenol in acetonitrile at 50 °C in the presence of K₂CO₃.

With substantial amounts of key intermediate **15** in hand, we investigated the final tandem Michael addition-Thorpe-Ziegler reaction (Fig 2) to generate the desired dihydropyrano[2,3-*c*]pyrazole. Reactant **17** [17] was easily available from ethyl acetoacetate and hydrazine hydrate (90% yield after re-crystallization). Finally, treatment of **17** with aldehyde **14** and malononitrile in EtOH resulted in precipitation of **4** [18] directly from the reaction mixture as a pure, white powder in 72% yield (Fig 3).




Fig 3. Reaction pathway for the synthesis of dihydropyrano[2,3-c]pyrazole 4. (i) Paraformaldehyde, AcOH, conc. HCl (aq), 70°C, 48 h (37%); (ii) hexamethylenetetramine, EtOH, H₂O, reflux, 16 h (37%); (iii) (a) NaBH₄, EtOH, (b) HBr, AcOH; (iv) 4-chloro-2-methylphenol, K₂CO₃, CH₃CN, 50°C, 3 h (99%); (v) hydrazine hydrate, EtOH, 0°C to 60°C, 3 h (90%); (vi) malonitrile, Et₃N, EtOH, 80°C, 17 min (72%).


































doi:10.1371/journal.pone.0162642.g003

1.3 Synthesis of 1,4-dihydropyrano-[2,3-c]pyrazoles. Next, the two-step protocol was applied to prepare a collection of 1,4-dihydropyrano[2,3-c]pyrazoles. All starting hydrazines were purchased from commercial suppliers. The corresponding β -keto esters were synthesized either according to Yuasa and Tsuruta [19] or by deprotonation of esters and subsequent reaction with ethyl acetate [20]. Aldehydes were all purchased or prepared in one step from **14** according to the procedure described for the synthesis of **15**. Following the general procedure (Fig 2), a library of 32 structurally diverse 1,4-dihydropyrano[2,3-c]pyrazoles were synthesized (Fig 4). The ease of this procedure should be emphasized. The reaction was performed at 80°C for 2 h and upon cooling to room temperature, nearly all products precipitated as discrete powders with no need for further purification.

2. Biological evaluation

2.1 Competitive binding and transactivation assays. The dihydropyrano[2,3-c]pyrazoles **4**, **10a-10ag** were tested for transactivation and affinity from competitive binding assay (Fig 4). Twenty-three of the dihydropyrano[2,3-c]pyrazoles dose-dependently displaced a labeled PPAR γ ligand *in vitro* in a TR-FRET competitive binding assay. Potency of binding as compared with known PPAR ligands was ranging from low affinity, as for compound **10c**, **10g**, **10h**, **10aa** and **10ad** with IC₅₀ > 100 μ M, to fairly high affinity, as observed for compound **10ae** and **10af** (IC₅₀ \leq 1 μ M) (Fig 4). Rosiglitazone was measured to displace with an IC₅₀ of 58 nM in this assay, in agreement with previously reported affinities [21]. Further, to examine receptor binding at a more functional level, we analysed the ability of the compounds to induce transcriptional activation in a cell based transactivation assay. Fourteen compounds were found to stimulate PPAR γ -mediated transactivation (Fig 4). As several relatively potent binders (compounds **10b**, **10f** and **10ag**) did not induce transcriptional activation, we speculated whether these compounds were behaving as antagonists. However, both cellular uptake and compound “metabolism” could influence the actual concentration, and it cannot be excluded that some of the compounds did not reach saturating concentrations in the cell-based transactivation assay.

It was indeed observed that most of the tested dihydropyrano[2,3-c]pyrazole compounds showed some activity against the PPAR γ receptor, with the exception of compounds **10e**, **10j**,

Entry	Substrate	Yield	hPPAR γ LBD transactivation	hPPAR γ LBD ligand displacement IC ₅₀ (μ M)	Entry	Substrate	Yield	hPPAR γ LBD transactivation	hPPAR γ LBD ligand displacement IC ₅₀ (μ M)
1		72%	+ ^c	32	18		58%	- ^a	-
2		57%	+ ^c	46	19		88%	- ^a	-
3		63%	- ^a	15.7	20		80%	+ ^c	14
4		12%	+ ^c	104	21		71%	- ^a	28
5		77%	- ^a	84	22		75%	- ^{aa}	-
6		78%	- ^a	-	23		79%	- ^a	-
7		39%	- ^a	3.0	24		8%	+ ^c	59
8		94%	+ ^c	105	25		58%	- ^a	87
9		89%	- ^a	173	26		84%	- ^a	-
10		89%	- ^a	75	27		84%	+ ^c	407
11		77%	- ^a	-	28		54%	+ ^c	-
12		58%	- ^a	-	29		56%	- ^a	-
13		88%	- ^a	-	30		15%	+ ^c	215
14		80%	+ ^c	14	31		7%	+ ^c	0.52
15		48%	- ^a	31	32		3%	+ ^c	1.1
16		50%	- ^a	-	33		8%	- ^a	14
17		50%	+ ^c	91					

^aSynthesized according to Scheme 1. ^bSynthesized according to Figure 2. ^cActivation (more than 2-fold). ^aNo activation (less than 2-fold).

Fig 4. Chemical and biological data for dihydropyrano[2,3-c]pyrazoles.

doi:10.1371/journal.pone.0162642.g004

10k, 10l, 10z, 10ab and 10ac. In analogy with previous SAR analyses of PPAR γ interacting compound series, the resulting SAR is not easily interpreted. However, it appears that the 2,5-dimethylaryl (**10a, 10g, 10p, 10ab, 10ae**) and the N1 4-Cl-phenyl moieties (**10ae, 10af**) are structural elements that confer transactivation to the dihydropyranozole scaffold. Furthermore, a strong correlation was observed between structure and binding affinity for the compounds, with the two NI 4-chlorophenyl-substituted dihydropyrano[2,3-c]pyrazoles (**10ae** and **10af**) both being identified as high-affinity binders with potency in the micro molar range.

The two most potent hits (**10ae** and **10af**) were further tested for transactivation selectivity towards all three PPAR subtypes. Both of the hits were found to be selective against PPAR γ .

2.2 Evaluation of PPAR γ binding mode. The binding modes of the dihydropyrano[2,3-c]pyrazoles **4, 10a-10ag** were explored with the multiple individual alignment approach [22], [23]. For this purpose, a model set of PPAR γ template ligands was generated on the basis of PPAR γ agonist-receptor complexes from the Protein Data Bank (PDB). More specifically, the template set was created from twenty-three PDB PPAR γ ligands accounting eleven full and twelve partial agonists (see [S1 File](#)). Each template was made from an agonist-bound PPAR γ structure and removal of the receptor leaving the template agonist in its crystal conformation.

Afterwards, individual alignment attempts of a given test molecule on each of the generated templates followed by reintroduction of the receptor and energy calculation, provided a hit list of matching binding modes. According to the targets encoded by these templates, a binding profile for the test ligand was generated.

In order to identify and implement rational threshold values for the docking screen, all twenty-three known PPAR γ model ligands were docked with the procedure described above. It was found that all model-ligands could be identified by their own template. To prioritize the best hits and reduce the number of false positives, the internal strain (dU), configurational similarity (dF) and alignment score (dS) constraints were set to a threshold value of 1. Furthermore, only compounds with an Autodock docking score (ΔG) more negative than a threshold value of -10 kcal/mol passed the docking screen, while any remaining compounds were discarded.

To validate the model, a test set of twenty-four known PPAR γ ligands, including nine full agonists, seven partial agonists, and eight inactives, was collected from the literature (see [S2 File](#)). The set of agonists was constituted by known antidiabetic drugs, including rosiglitazone (**1**, TZD), farglitazar (non-TZD) and other biological relevant agonist with either selective PPAR γ or dual PPAR α/γ , PPAR δ/γ selectivity, but no pan PPAR agonists were included. It was ensured that the compounds covered a broad range of activities, from weak to medium and strong agonists. The inactives were manually selected from a set of PPAR γ inactive compounds that were structurally similar to the selected PPAR γ agonists. Upon evaluation of the test set of PPAR γ ligands in the model, seven of the nine full agonists were found to match a full agonist template (with the exception of CID-11384748 and CID-44411945) with four of them matching on more than one template. Six out of seven partial agonists were observed to align on a partial agonist template (with the exception of CID-15069295). Unfortunately, due to the high structural similarity between actives and inactives, the model was not always able to discriminate between the two, leading to several of the inactive test compounds being identified as actives (false positives). However, in combination with cell-based transactivation experiments, the presented model provides a promising analytical tool to evaluate and visualize the effect of ligand chemical structure in respect to receptor binding mode and biological activity.

Next, the methodology was applied to the reference dihydropyrano[2,3-c]pyrazole PPAR γ partial agonist **4**. The ligand **4** was found to match two of the partial agonist templates (CID-2742752 and CID-10229498). From further inspection of the suggested binding modes, it was concluded that the CID-10229498 binding mode is reasonable ([Fig 5](#)). The dihydropyrano [2,3-c]pyrazole group of **4** was observed to make several stabilizing hydrophobic interactions in the β -sheet regions, while the amino group formed a hydrogen bond with Ile281 located in Helix3. Furthermore, the central benzene ring made strong interactions with Cys285.

Finally, we analysed the binding modes of 32 novel potential PPAR γ partial agonists (**10a-10ag**) by incorporation in twenty-three ligand templates in the individual alignment model. Of the 32 compounds analysed by the model, we were able to identify binding modes for twenty-one of them. All ligands without identifiable binding modes were found to be low affinity binders ($IC_{50} < 30$ mM) in the ligand displacement experiments.

Six of the dihydropyrano[2,3-c]pyrazole compounds (**10q**, **10r**, **10s**, **10ae**, **10af** and **10ag**) displaying highest transactivation potential were found to match the same CID-10229498 template as reference dihydropyrano[2,3-c]pyrazole **4**. A closer inspection of the docked ligands revealed that although all of the six ligands matched the same template, they clustered around two distinct binding modes. A strong correlation between binding mode and chemical structure was observed. The ligands **10q**, **10r** and **10s** share high structural similarity with dihydropyrano[2,3-c]pyrazole **4** and were all observed to have identical alignments in the CID-10229498 template displaying the same types of interactions as described for **4**. However, the presence of a substituent on the dihydropyrano[2,3-c]pyrazole N1 clearly influences the

receptor ligand complex. The high-affinity ligands **10ae**, **10af** and **10ag** have a N1 phenyl-substituent in common. Although they were recognized to match the CID-10229498 template, they seemed to adopt a different but mutually similar scaffold positioning (Fig 6). The altered ligand structure induces a relocation of the ligand in the receptor, allowing the dihydropyrano [2,3-c]pyrazole phenyl-group to participate in several stabilizing hydrophobic interactions with Ser342 and Ile341 in the β -sheet regions. The altered positioning places the pyrano[2,3-c]pyrazole moiety in close proximity to Helix3, where strong interactions with Cys285 are observed. Furthermore, the carbonitrile group may interact with Arg288.

Conclusions

In here we report dihydropyrano[2,3-c]pyrazoles as a novel class of PPAR γ partial agonists. A synthetically tractable scale-up synthesis of lead compound dihydropyrano[2,3-c]pyrazole **4** has been developed for compound validation as well as further medicinal chemistry efforts. Furthermore, the synthesis and biological evaluation of a series of novel dihydropyrano[2,3-c]pyrazole derivatives with high structural variation has been accomplished. Competitive binding and transactivation assay experiments showed that most of the compounds displayed some activity against PPAR γ with the two NI 4-chlorophenyl-substituted dihydropyrano[2,3-c]pyrazoles (**10ae** and **10af**) both being identified as selective high-affinity binders with potency in the micro molar range.

Moreover, a novel approach based on multiple individual flexible alignment for the identification of ligand binding interactions in PPAR γ was developed. In combination with cell-based transactivation experiments, the flexible alignment model provides an excellent analytical tool to evaluate and visualize the effect of ligand chemical structure in respect to receptor binding mode and biological activity.

Experimental section

1. Materials and measurements

All reagents used were commercially available. All solvents were of HPLC grade. Analytical LC-MS analysis was performed on a Waters AQUITY UPLC system equipped with PDA and




Fig 5. The ligand 4 presented in the aligned binding mode on CID-10229498.

doi:10.1371/journal.pone.0162642.g005




Fig 6. The ligands 4 (orange) and 10ag (green) shown on top of each other from alignment on CID-10229498. The altered ligand structure induces a relocation of the ligand in the receptor, allowing the phenyl-substituent on the dihydropyrano[2,3-c]pyrazole N1 in 10ag to participate in several stabilizing hydrophobic interactions in the β -sheet regions.

doi:10.1371/journal.pone.0162642.g006

SQD MS detector; column: AQUITY UPLC BEH C18 1.7 μ m, 2.1 x 50mm; column temp: 65°C; solvent A: 0.1% formic acid (aq); solvent B: 0.1% formic acid (acetonitrile); gradient: 5% B to 100% B in 2.4 min, hold for 0.1 min, total run-time ca. 2.6 min. ^1H and ^{13}C NMR 300 MHz spectra were recorded on a Varian Mercury 300 BB spectrometer at room temperature. All NMR spectra were recorded using CDCl_3 or $\text{DMSO}-d_6$ as solvents

2. Synthesis

2.1 1,3-Bis(chloromethyl)-4,6-dimethylbenzene (12) [15]. A stirred solution of *m*-xylene (100.0 mL, 0.818 mol), paraformaldehyde (58.0 g, 1.93 mol), acetic acid (99%, 200 mL) and conc. HCl (aq, 800 mL) was mechanically stirred for 48 h at 70°C. During the last part of the reaction time (18 h), the product precipitated as a white solid. The reaction mixture was cooled to room temperature, and the product isolated by filtration. The filter cake was washed with water and then dissolved in boiling heptane (200 mL). The boiling heptane phase was washed with hot 10% aqueous NaHCO_3 (50 mL) and then phase separated. Upon cooling to room temperature, the product precipitated as a white solid. Yield: 60.3 g (37%). ^1H NMR (300 MHz, CDCl_3): δ = 7.26 (s, 1H, ArH), 7.06 (s, 1H, ArH), 4.58 (s, 4H, CH_2Cl), 2.40 (s, 6H, 2 \times Ar CH_3); ^{13}C NMR (75 MHz, CDCl_3): δ = 138.09, 133.61, 133.38, 131.33, 44.50, 18.54.

2.2 4,6-Dimethylisophthalaldehydebenzene (13) [16]. A stirred suspension of 1,3-bis(chloromethyl)-4,6-dimethylbenzene (12) (80.0 g, 0.394 mol), hexamethylenetetramine (110.5 g, 0.789 mol), ethanol (1000 mL) and water (500 mL) was refluxed for 16 h. The hot reaction

mixture was filtered and the filtrate cooled to room temperature. The pH was adjusted to 1–2 with 4.0 M HCl (aq) and extracted with CH₂Cl₂ (3 × 700 mL). The combined organic phase was dried with Na₂SO₄, filtered and solution concentrated to around 100 mL under reduced pressure. This resulted in precipitation of 4,6-dimethylisophthalaldehydebenzene as a white solid, which was isolated by filtration. Yield: 23.3 g (37%). ¹H NMR (300 MHz, CDCl₃): δ = 10.25 (d, *J* = 0.6 Hz, 2H, 2 × CHO), 8.22 (s, 1H, ArH), 7.18 (s, 1H, ArH), 2.70 (d, *J* = 0.9 Hz, 6H, 2 × ArCH₃); ¹³C NMR (75 MHz, CDCl₃): δ = 191.71, 146.38, 136.94, 135.82, 132.78, 20.18; UPLC-MS (ESI): *m/z* = 163.1 (M+H)⁺.

2.3 5-Bromomethyl-2,4-dimethylbenzaldehyde (14). 4,6-Dimethylisophthalaldehyde (23.3 g, 0.144 mol) was dissolved in EtOH (500 mL) with vigorous stirring at room temperature. The reaction mixture was then treated with NaBH₄ (0.55 g, 0.0146 mol) in one portion. After stirring for 2 h at room temperature, the solution was treated with another portion of NaBH₄ (0.55 g, 0.0146 mol). After additional 2 h of stirring, the reaction mixture was treated with a third portion of NaBH₄ (0.38 g, 0.010 mol) and the reaction mixture was left with stirring overnight at room temperature. EtOH was removed under reduced pressure and the remaining oil was treated with boiling water (200 mL) and the mixture cooled to room temperature. Acidification to pH 1–2 with 4.0 M HCl (aq) and treatment with brine (200 mL) and EtOAc (300 mL) afforded a two-phase system, which was separated. The water phase was extracted with EtOAc (2 × 200 mL). The combined organic phase was washed with brine (200 mL), dried over Na₂SO₄, filtered and concentrated *in vacuo*. The resulting yellow oil was purified by flash column chromatography on silica gel (eluent: heptane/EtOAc, 95:5) to afford 7.5 g (23%) of 5-bromomethyl-2,4-dimethyl-benzaldehyde (14) as a white solid and 6.0 g (26%) of recovered 4,6-dimethylisophthalaldehyde (13). ¹H NMR (300 MHz, CDCl₃): δ = 10.20 (s, 1H, CHO), 7.74 (s, 1H, ArH), 7.10 (s, 1H, ArH), 4.53 (s, 2H, CH₂Br), 2.63 (s, 3H, ArCH₃), 2.45 (s, 3H, ArCH₃); ¹³C NMR (75 MHz, CDCl₃): δ = 191.82, 143.80, 141.37, 134.54, 134.21, 133.46, 132.64, 31.20, 19.27, 19.13; UPLC-MS (ESI): *m/z* = 227.1, 229.1 (M+H)⁺.

2.4 5-((4-Chloro-2-methylphenoxy)methyl)-2,4-dimethylbenzaldehyde (15) [17]. 5-Bromomethyl-2,4-dimethylbenzaldehyde (1.0 g, 4.40 mmol) and 4-chloro-2-methylphenol (657 mg, 4.62 mmol) were dissolved in acetonitrile (50 mL) and treated with K₂CO₃ (912 mg, 6.60 mmol). The suspension was heated to 50 °C with stirring. After 3 h the precipitate was removed by filtration and the filtrate concentrated *in vacuo*. Purification by flash column chromatography on silica gel (eluent: heptane/EtOAc 95:5) to afford the aldehyde 15 as a white solid. Yield: 1.26 g (99%). ¹H NMR (300 MHz, CDCl₃): δ = 10.22 (d, *J* = 0.9 Hz, 1H, CHO), 7.84 (s, 1H, ArH), 7.20–7.07 (m, 2H, ArH), 6.83 (dd, *J* = 8.0, 1.1 Hz, 1H, ArH), 5.02 (s, 2H, OCH₂Ar), 2.65 (s, 3H, ArCH₃), 2.40 (s, 3H, ArCH₃), 2.22 (d, *J* = 0.8 Hz, 3H, ArCH₃); ¹³C NMR (75 MHz, CDCl₃): δ = 192.29, 155.38, 143.27, 140.71, 134.17, 133.27, 132.31, 132.26, 130.71, 129.05, 126.49, 125.59, 112.35, 68.23, 19.31, 19.23, 16.38; UPLC-MS (ESI): *m/z* = 289.2 (M+H)⁺.

2.5 3-Methyl-1H-pyrazol-5(4H)-one (17) [18]. Ethyl acetoacetate (10.0 g, 0.077 mol) was dissolved in EtOH (150 mL) and cooled to 0 °C. With stirring the solution was treated dropwise with hydrazine hydrate (3.5 g, 0.070 mol). After complete addition the solution was heated to 60 °C for 3 h and the concentrated *in vacuo*. The resulting solid was re-crystallized from Et₂O/EtOAc/EtOH to give 17 as a light yellow powder. Yield: 6.2 g (90%). ¹H NMR (300 MHz, DMSO-*d*₆): δ = 10.40 (bs, 2H, NH + OH (tautomeric enol form)), 5.21 (s, 1H, CH = COH (tautomeric enol form)), 2.08 (s, 3H, ArCH₃); ¹³C NMR (75 MHz, CDCl₃): δ = 161.22, 139.54, 89.03 (tautomeric enol form), 49.37 (tautomeric keto form), 11.28.

2.6 6-Amino-4-(5-chloro-2-methylphenoxy)methyl-2,4-dimethylphenyl-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (4) [19]. 5-((4-chloro-2-methylphenoxy)methyl)-2,4-dimethyl-benzaldehyde (800 mg, 2.77 mmol) and malonitrile (183 mg, 2.77 mmol) was suspended in EtOH (30 mL) and treated with Et₃N (280 mg, 2.77 mmol). The

solution was placed in a pre-heated oil bath (80°C) and stirred for 2 min., followed by addition of 3-methyl-1*H*-pyrazol-5(4*H*)-one **17** (272 mg, 2.77 mmol). The solution was stirred at 80°C for 15 min. Cooling of the reaction to room temperature, resulted in precipitation of **4** as a white solid, which was isolated by filtration. Yield: 862 mg (72%). ¹H NMR (300 MHz, DMSO-*d*₆): δ = 12.06 (s, 1H, ArNH), 7.21–7.18 (m, 1H, ArH), 7.14 (d, *J* = 8.8 Hz, 1H, ArH), 7.06 (s, 1H, ArH), 7.03–6.96 (m, 2H, ArH), 6.82 (s, 2H, ArNH₂), 4.99 (s, 2H, ArCH₂OAr), 4.80 (s, 1H, CHAr), 2.28 (s, 3H, ArCH₃), 2.24 (s, 3H ArCH₃), 2.06 (s, 3H, ArCH₃), 1.63 (s, 3H ArCH₃); ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 160.76, 155.15, 155.09, 139.44, 135.27, 134.38, 134.26, 132.85, 132.19, 129.91, 128.69, 128.40, 126.30, 123.80, 120.88, 113.32, 97.64, 67.80, 56.99, 49.28, 18.53, 17.94, 15.78, 9.57; UPLC-MS (ESI): *m/z* = 435.3 (M+H)⁺.

2.7 General synthetic procedure for 1*H*-pyrazol-5(4*H*)-one compounds. A solution of β -ketoester (0.011 mmol) in ethanol (50 mL) was treated with the appropriate hydrazine (0.011 mmol) at 0°C. The mixture was allowed to reach room temperature and then heated to 60°C for 3 h. The solvent was removed *in vacuo* and the residue purified by recrystallization or column chromatography.

2.7.1 3-Benzyl-1*H*-pyrazol-5(4*H*)-one. The title compound was synthesized from methyl 3-oxo-phenylbutanoate (2.2 g) and hydrazine hydrate (0.44 g) according to the general procedure. The product was purified by recrystallization from toluene/heptane and isolated as a white/yellow powder. Yield: 0.84 g (42%). M.p.: 190°C. ¹H NMR (300 MHz, DMSO-*d*₆): δ = 3.35 (s, 1H), 3.78 (s, 2H), 5.21 (s, 1H), 7.20–7.32 (m, 5H).

2.8 General synthetic procedure for dihydropyrano[2,3-*c*]pyrazole compounds (10a–10ah). The appropriate aldehyde (0.0014 mmol) and malononitrile (0.095 g, 0.0014 mmol) was suspended in ethanol (20 ml) and treated with Et₃N (0.145 g, 0.0014 mmol). The solution was raised into an preheated oil bath (80°C) and stirred for 2 min, followed by the addition of the appropriate 1*H*-pyrazol-5(4*H*)-one (0.0014 mmol). After stirring at 80°C for 15 min, the solution was cooled to room temperature. The resulting precipitate was isolated by filtration and washed ethanol.

2.8.1 6-Amino-3-benzyl-4-(2,5-dimethylphenyl)-1,4-dihydropyrano[2,3-*c*]pyrazole-5-carbonitrile (10a). The title compound was synthesized from 2,5-dimethylbenzaldehyde (0.188 g) and 3-benzyl-1*H*-pyrazol-5(4*H*)-one (0.244 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.512 g (57%). ¹H NMR (300 MHz, DMSO-*d*₆): δ = 12.33 (s, 1H, ArNH), 7.13 (s, 3H, 3 × ArH), 7.04–6.79 (m, 4H, 4 × ArH), 6.80–6.63 (m, 3H, ArH + ArNH₂), 4.70 (s, 1H, CHAr), 3.56 (d, *J* = 15.6 Hz, 1H, ArCHH), 3.27 (d, *J* = 15.7 Hz, 1H, ArCHH), 2.15 (s, 3H, ArCH₃), 2.11 (s, 3H, ArCH₃). ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 160.53, 155.23, 138.08, 137.34, 135.14, 132.02, 130.52, 129.50, 129.43, 128.31, 127.98, 127.43, 126.28, 120.69, 97.59, 56.90, 49.38, 30.36, 20.68, 18.42. IR (neat): 1486, 1597, 1632, 2194, 3088, 3243, 3473. UPLC-MS (ESI): *m/z* = 357.2 (M+H)⁺.

2.8.2 6-Amino-3-benzyl-5(*o*-tolyl)-1,4-dihydropyrano[2,3-*c*]pyrazole-5-carbonitrile (10b). The title compound was synthesized from 2-methyl-benzaldehyde (0.172 g) and 3-benzyl-1*H*-pyrazol-5(4*H*)-one (0.244 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.312 g (63%). M.p.: 211–213°C. ¹H NMR (300 MHz, DMSO-*d*₆): δ = 12.34 (s, 1H, ArNH), 7.93–6.15 (m, 11H, 9 × ArH + ArNH₂), 4.74 (s, 1H, CHAr), 3.58 (d, *J* = 16.1 Hz, 1H, ArCHH), 3.24 (d, *J* = 16.2 Hz, 1H, ArCHH), 2.12 (s, 3H, ArCH₃). ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 160.59, 155.23, 141.95, 138.07, 137.34, 135.12, 130.62, 129.07, 128.38, 127.99, 126.73, 126.37, 126.31, 120.66, 97.54, 56.76, 56.09, 30.35, 18.77. IR (neat): 1208, 1387, 1640, 2201, 3218, 3312, 3439. UPLC-MS (ESI): *m/z* = 343.2 (M+H)⁺.

2.8.3 6-Amino-3-benzyl-4-(2,4-dimethylphenyl)-1,4-dihydropyrano[2,3-*c*]pyrazole-5-carbonitrile (10c) [24]. The title compound was synthesized from 2,4-dimethylbenzaldehyde (0.188 g) and 3-benzyl-1*H*-pyrazol-5(4*H*)-one (0.244 g) according to the general

procedure. The product was isolated as a white powder. Yield: 0.312 g (63%). M.p.: 211–213°C. ^1H NMR (300 MHz, DMSO- d_6): δ = 12.33 (s, 1H, ArNH), 7.23–7.10 (m, 3H, ArH), 7.01–6.81 (m, 4H, ArH), 6.78–6.65 (m, 3H, ArH + ArNH $_2$), 4.70 (s, 1H, CHAr), 3.56 (d, J = 15.6 Hz, 1H, ArCHH), 3.27 (d, J = 15.7 Hz, 1H, ArCHH), 2.15 (s, 3H, ArCH $_3$), 2.11 (s, 3H, ArCH $_3$). ^{13}C NMR (75 MHz, DMSO- d_6): δ = 160.49, 155.20, 138.94, 138.05, 137.37, 135.64, 134.87, 131.26, 129.05, 128.33, 127.99, 126.95, 126.24, 120.67, 97.63, 56.94, 50.43, 30.33, 20.58, 18.69. IR (neat): 1208, 1387, 1640, 2201, 3218, 3312, 3439. UPLC-MS (ESI): m/z = 357.2 (M+H) $^+$.

2.8.4 6-Amino-3-benzyl-4-(4-methoxy-2,3-dimethylphenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10d) [25]. The title compound was synthesized from 2,3-dimethyl-4-methoxybenzaldehyde (0.236 g) and 3-benzyl-1H-pyrazol-5(4H)-one (0.244 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.428 g (77%). ^1H NMR (300 MHz, DMSO- d_6): δ 12.30 (s, 1H, ArNH), 7.18–7.08 (m, 3H, ArH), 6.86–6.69 (m, 6H, 4 (ArH + ArNH $_2$), 4.74 (s, 1H, CHAr), 3.73 (s, 3H, ArOCH $_3$), 3.55 (d, J = 15.7 Hz, 1H, ArCHH), 3.26 (d, J = 15.7 Hz, 1H, ArCHH), 2.03 (s, 6H, 2 \times ArCH $_3$). ^{13}C NMR (101 MHz, DMSO- d_6) δ = 160.3, 155.7, 155.1, 138.0, 137.4, 137.3, 135.0, 128.1, 127.9, 126.1, 120.7, 108.2, 98.3, 58.0, 55.3, 30.3, 14.7, 11.9; IR (neat): 1103, 1399, 2192, 3080, 3236, 3482. UPLC-MS (ESI): m/z = 387.2 (M+H) $^+$.

2.8.5 6-Amino-4-(4-chlorophenyl)-3-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10e) [26]. The title compound was synthesized from 4-chlorobenzaldehyde (0.197 g) and 3-phenyl-1H-pyrazol-5(4H)-one (0.224 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.381 g (78%). ^1H NMR (300 MHz, DMSO- d_6): δ = 12.93 (s, 1H, ArNH), 7.50–7.43 (m, 2H, ArH), 7.37–7.23 (m, 5H, 5 (ArH), 7.17–7.09 (m, 2H, 2 (ArH), 6.98 (s, 2H, ArNH $_2$), 5.06 (s, 1H, CHAr); ^{13}C -NMR (100 MHz, DMSO- d_6): δ = 160.56, 156.35, 144.04, 138.47, 131.54, 129.68, 129.07, 128.93, 128.87, 128.74, 126.69, 120.92, 97.40, 58.24, 36.48. UPLC-MS (ESI): m/z = 349.1 (M+H) $^+$.

2.8.6 6-Amino-4-(2,4-dichlorophenyl)-3-methyl-1-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10f). The title compound was synthesized from from 2,4-dichlorobenzaldehyde (0.243 g) and 3-phenyl-1H-pyrazol-5(4H)-one (0.224 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.208 g (39%). ^1H NMR (300 MHz, DMSO- d_6): δ = 5.45 (s, 1H), 7.00–7.50 (m, 10H), 12.92 (s, 1H). ^{13}C NMR (75 MHz, DMSO- d_6): δ = 33.67, 49.26, 55.96, 96.14, 120.02, 126.13, 127.80, 128.38, 128.58, 131.98, 132.08, 132.97, 138.05, 140.22, 156.10, 160.58. UPLC-MS (ESI): m/z = 383.1 (M+H) $^+$.

2.8.7 6-Amino-4-(2,5-dimethylphenyl)-3-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10g) [25]. The title compound was synthesized from from 2,5-dimethylbenzaldehyde (0.243 g) and 3-phenyl-1H-pyrazol-5(4H)-one (0.224 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.208 g (39%). ^1H NMR (300 MHz, DMSO- d_6): δ = 5.45 (s, 1H), 7.00–7.50 (m, 10H), 12.92 (s, 1H). ^{13}C NMR (75 MHz, DMSO- d_6): δ = 33.67, 49.26, 55.96, 96.14, 120.02, 126.13, 127.80, 128.38, 128.58, 131.98, 132.08, 132.97, 138.05, 140.22, 156.10, 160.58. UPLC-MS (ESI): m/z = 343.2 (M+H) $^+$.

2.8.8 6-Amino-3,4-diphenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10h) [27]. The title compound was synthesized from from benzaldehyde (0.149 g) and 3-phenyl-1H-pyrazol-5(4H)-one (0.224 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.392 g (89%). ^1H NMR (300 MHz, DMSO- d_6): δ = 12.84 (s, 1H, ArNH), 7.44 (d, J = 7.1 Hz, 2H, ArH), 7.33–7.24 (m, 3H, ArH), 7.22–7.17 (m, 2H, ArH), 7.13–7.07 (m, 3H, ArH), 6.93 (s, 2H + ArNH $_2$), 4.97 (s, 1H, CHAr). ^{13}C NMR (75 MHz, DMSO- d_6): δ = 160.05, 156.03, 144.69, 137.87, 128.63, 128.57, 128.34, 128.31, 127.31, 126.63, 126.20, 120.63, 97.42, 58.26, 36.74. UPLC-MS (ESI): m/z = 315.1 (M+H) $^+$.

2.8.9 6-Amino-4-(2,4-dimethylphenyl)-3-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10i). The title compound was synthesized from 2,4-dimethylbenzaldehyde (0.243 g) and 3-phenyl-1*H*-pyrazol-5(4*H*)-one (0.224 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.427 g (89%). ^1H NMR (300 MHz, DMSO- d_6): δ = 12.83 (s, 1H, ArNH), 7.64–7.09 (m, 5H, ArH), 6.89–6.81 (m, 4H, 2 (ArH + 2 (ArNH $_2$)), 6.77 (d, J = 7.9, 1H, ArH), 5.15 (s, 1H, CHAr), 2.30 (s, 3H, ArCH $_3$), 2.15 (s, 3H, ArCH $_3$); ^{13}C NMR (100 MHz, DMSO- d_6): δ = 159.98, 156.26, 137.70, 135.27, 134.30, 130.99, 128.79, 128.51 (two overlapping signals), 128.27, 127.01, 126.07 (two overlapping signals), 120.63, 97.78, 57.81, 20.46 (two overlapping signals), 18.81. UPLC-MS (ESI): m/z = 343.2 (M+H) $^+$.

2.8.10 6-Amino-4-(4-methoxy-2,3-dimethylphenyl)-3-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10j). The title compound was synthesized from 2,3-dimethyl-4-methoxybenzaldehyde (0.236 g) and 3-phenyl-1*H*-pyrazol-5(4*H*)-one (0.224 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.401 g (77%). ^1H NMR (300 MHz, DMSO- d_6): δ = 12.84 (s, 1H, ArNH), 7.94–7.01 (m, 5H, ArH), 6.78–6.72 (m, 4H, 2 (ArH + ArNH $_2$)), 5.23 (s, 1H, CHAr), 3.65 (s, 3H, ArOCH $_3$), 2.26 (s, 3H, ArCH $_3$), 2.05 (s, 3H, ArCH $_3$). ^{13}C NMR (75 MHz, DMSO- d_6): δ = 159.87, 156.29, 155.25, 137.56, 134.50, 128.84, 128.51, 128.26, 126.74, 126.10, 123.54, 120.73, 109.81, 108.46, 98.46, 58.54, 55.17, 15.06, 12.06 (two overlapping signals). UPLC-MS (ESI): m/z = 373.2 (M+H) $^+$.

2.8.11 6-Amino-4-(4-fluorophenyl)-3-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10k) [26]. The title compound was synthesized from 4-fluorobenzaldehyde (0.174 g) and 3-phenyl-1*H*-pyrazol-5(4*H*)-one (0.224 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.270 g (58%). ^1H NMR (400 MHz, DMSO- d_6): δ = 12.90 (s, 1H, ArNH), 7.48–7.39 (m, 2H, 2 \times ArH), 7.34–7.22 (m, 3H, 3 \times ArH), 7.17–7.09 (m, 2H, 2 \times ArH), 7.06–6.97 (m, 2H, 2 \times ArH), 6.94 (s, 2H, ArNH $_2$), 5.04 (s, 1H, CHAr); ^{13}C NMR (100 MHz, DMSO- d_6): δ = 160.77 (d, J = 241 Hz), 160.02, 155.88, 140.80 (d, J = 3 Hz), 137.98, 129.20 (d, J = 3 Hz), 128.55, 128.52, 128.35, 126.25, 120.52, 115.02 (d, J = 21 Hz), 97.27, 58.09, 35.91. UPLC-MS (ESI): m/z = 333.1 (M+H) $^+$.

2.8.12 6-Amino-3-phenyl-4-(*o*-tolyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10l). The title compound was synthesized from 2-methylbenzaldehyde (0.168 g) and 3-phenyl-1*H*-pyrazol-5(4*H*)-one (0.224 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.405 g (88%). ^1H NMR (300 MHz, DMSO- d_6): δ = 12.84 (s, 1H, ArNH), 7.33–7.20 (m, 6H, 5 \times ArH), 7.06–6.88 (m, 3H, 3 \times ArH), 6.91 (d, J = 2.2 Hz, 1H, ArH), 6.88 (s, 2H, ArNH $_2$), 5.19 (s, 1H, CHAr), 2.33 (s, 3H, ArCH $_3$); ^{13}C NMR (100 MHz, DMSO- d_6): δ = 160.09, 156.23, 142.67, 137.84, 134.59, 130.36, 128.75, 128.59, 128.46, 128.30, 126.46, 126.31, 126.14, 120.59, 97.70, 57.55, 33.20, 18.88. UPLC-MS (ESI): m/z = 329.1 (M+H) $^+$.

2.8.13 6-Amino-4-(2,4-dimethylphenyl)-3-propyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10m) [25]. The title compound was synthesized from 2,4-dimethylbenzaldehyde (0.188 g) and 3-propyl-1*H*-pyrazol-5(4*H*)-one (0.177 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.345 g (80%). ^1H NMR (300 MHz, DMSO- d_6): δ = 12.07 (s, 1H, ArNH), 6.96–6.85 (m, 3H, ArH), 6.80 (s, 2H, ArNH $_2$), 4.83 (s, 1H, CHAr), 2.20 (s, 6H, 2 \times ArCH $_3$), 2.17–1.88 (m, 2H, CH $_2$), 1.29–0.91 (m, 2H, CH $_2$), 0.57 (t, J = 7.3 Hz, 3H, CH $_3$). ^{13}C NMR (75 MHz, DMSO- d_6): δ = 160.59, 155.00, 139.54, 139.20, 135.51, 134.73, 131.21, 129.03, 126.86, 120.78, 97.20, 56.94, 26.28, 20.98, 20.57, 18.78, 13.36 (two overlapping aliphatic signals). UPLC-MS (ESI): m/z = 309.2 (M+H) $^+$.

2.8.14 6-Amino-4-(4-chlorophenyl)-3-propyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10n). The title compound was synthesized from 4-chlorobenzaldehyde (0.197 g) and 3-propyl-1*H*-pyrazol-5(4*H*)-one (0.177 g) according to the general procedure. The

product was isolated as a white powder. Yield: 0.441 g (48%). ^1H NMR (300 MHz, DMSO- d_6): δ = 12.15 (s, 1H, ArNH), 7.37 (d, J = 8.4 Hz, 2H, 2 \times ArH), 7.19 (d, J = 8.4 Hz, 2H, 2 \times ArH), 6.91 (s, 2H, ArNH $_2$), 4.63 (s, 1H, CHAr), 2.17 (ddd, J = 15.0, 8.5, 6.7 Hz, 1H, ArCHHCH $_2$), 2.05 (ddd, J = 14.7, 8.5, 6.4 Hz, 1H, ArCHHCH $_2$), 1.33–1.06 (m, 2H, CH $_2$ CH $_2$ CH $_3$), 0.63 (t, J = 7.3 Hz, 3H CH $_2$ CH $_3$); ^{13}C NMR (100 MHz, DMSO- d_6): δ = 160.75, 154.59, 143.91, 139.82, 131.23, 129.41, 128.40, 120.63, 96.90, 56.97, 35.72, 26.19, 20.95, 13.31. UPLC-MS (ESI): m/z = 315.1 (M+H) $^+$.

2.8.15 6-Amino-4-phenyl-3-propyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10o). The title compound was synthesized from benzaldehyde (0.149 g) and 3-propyl-1H-pyrazol-5(4H)-one (0.177 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.441 g (48%). ^1H NMR (300 MHz, DMSO- d_6): δ = 12.10 (s, 1H, ArNH), 7.36–7.27 (m, 2H, 2 \times ArH), 7.25–7.19 (m, 1H, ArH), 7.18–7.13 (m, 2H, 2 \times ArH), 6.85 (s, 2H, ArNH $_2$), 4.58 (s, 1H, CHAr), 2.16 (ddd, J = 14.9, 8.6, 6.6 Hz, 1H, ArCHHCH $_2$), 2.04 (ddd, J = 14.7, 8.6, 6.4 Hz, 1H, ArCHHCH $_2$), 1.30–1.03 (m, 2H, CH $_2$ CH $_2$ CH $_3$), 0.61 (t, J = 7.3 Hz, 3H CH $_2$ CH $_3$); ^{13}C NMR (100 MHz, DMSO- d_6): δ = 160.71, 154.63, 144.87, 139.76, 128.39, 127.52, 126.75, 120.77, 97.33, 57.39, 36.44, 26.21, 20.93, 13.31. UPLC-MS (ESI): m/z = 281.1 (M+H) $^+$.

2.8.16 6-Amino-4-(2,5-dimethylphenyl)-3-propyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10p). The title compound was synthesized from 2,5-dimethylbenzaldehyde (0.188 g) and 3-propyl-1H-pyrazol-5(4H)-one (0.177 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.216 g (50%). ^1H NMR (300 MHz, DMSO- d_6): δ = 12.09 (s, 1H, ArNH), 7.35–6.45 (m, 5H, 3 \times ArH + ArNH $_2$), 4.79 (s, 1H, CHAr), 2.20–1.75 (m, 2H, ArCH $_2$), 2.18 (s, 6H, 2 \times ArCH $_3$), 1.39–0.83 (m, 2H, CH $_2$ CH $_2$ CH $_3$), 0.53 (t, J = 7.7 Hz, 3H, CH $_2$ CH $_3$). ^{13}C NMR (75 MHz, DMSO- d_6): δ = 160.65, 155.00, 142.08, 139.57, 135.00, 131.89, 130.50, 129.45, 127.42, 127.35, 120.80, 97.21, 56.84, 26.28, 20.94, 20.66, 18.46, 13.31 (two overlapping). UPLC-MS (ESI): m/z = 309.2 (M+H) $^+$.

2.8.17 6-Amino-4-(5-((2,3-dichlorophenoxy)methyl)-2,4-dimethylphenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10q). The title compound was synthesized from 5-((3,4-dichlorophenoxy)methyl)-2,4-dimethylbenzaldehyde (0.433 g) and 3-methyl-1H-pyrazol-5(4H)-one (0.137 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.529 g (83%). ^1H NMR (300 MHz, DMSO- d_6): δ = 12.06 (s, 1H, ArNH), 7.51 (m, 1H, ArH), 7.29 (m, 1H, ArH), 7.00 (m, 3H, ArH), 6.83 (m, 2H, ArNH $_2$), 5.02 (s, 2H, ArCH $_2$ OAr), 4.80 (s, 1H, CHAr), 2.23 (s, 6H, 2 \times ArCH $_3$), 1.64 (s, 3H ArCH $_3$). ^{13}C NMR (75 MHz, DMSO- d_6): δ = 160.74, 157.84, 155.06, 135.31, 135.24, 132.54, 132.03, 131.99, 131.55, 130.86, 129.87, 129.83, 122.51, 120.79, 116.77, 115.95, 97.43, 68.93, 56.74, 40.35, 18.56, 18.04 (two overlapping), 9.59. UPLC-MS (ESI): m/z = 455.1 (M+H) $^+$.

2.8.18 6-Amino-4-(2,4-dimethyl-(5-(phenoxy)methyl)phenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10r). The title compound was synthesized from 2,4-dimethyl-5-phenoxy-methyl-benzaldehyde (0.336 g) and 3-methyl-1H-pyrazol-5(4H)-one (0.137 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.400 g (74%). ^1H NMR (300 MHz, DMSO- d_6): δ = 12.06 (s, 1H, ArNH), 7.38–7.19 (m, 3H, ArH), 7.14–6.87 (m, 4H, ArH), 6.83 (s, 2H, ArNH $_2$), 4.97 (s, 2H, ArCH $_2$ OAr), 4.81 (s, 1H, CHAr), 2.25 (s, 6H 2 \times ArCH $_3$), 1.64 (s, 3H ArCH $_3$). ^{13}C NMR (75 MHz, DMSO- d_6): δ = 160.74, 158.38, 155.07, 139.21, 135.34, 135.03, 134.83, 132.75, 132.44, 129.72, 129.41, 120.81, 120.67, 114.86, 97.38, 68.04, 56.80, 18.55, 18.04 (two overlapping), 9.62. UPLC-MS (ESI): m/z = 387.2 (M+H) $^+$.

2.8.19 6-Amino-4-(5-(((5-chloroquinolin-8-yl)oxy)methyl)-2,4-dimethylphenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10s). The title compound was synthesized from 5-(((5-chloroquinolin-8-yl)oxy)methyl)-2,4-dimethylbenzaldehyde (0.456 g)

and 3-methyl-1*H*-pyrazol-5(4*H*)-one (0.137 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.297 g (63%). ¹H NMR (300 MHz, DMSO-*d*₆): δ = 12.04 (s, 1H, ArNH), 9.05–8.82 (m, 1H, ArH), 8.57–8.38 (m, 1H, ArH), 7.80–7.53 (m, 2H, ArH), 7.28 (m, 1H, ArH), 7.14 (s, 1H, ArH), 7.01 (s, 1H, ArH), 6.83 (s, 2H, ArNH₂), 5.19 (s, 2H, ArCH₂OAr), 4.86 (s, 1H, CHAr), 2.31 (s, 3H ArCH₃), 2.29 (s, 3H ArCH₃), 1.70 (s, 3H ArCH₃). ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 160.75, 155.06, 153.64, 149.86, 140.49, 135.50, 135.03, 132.50, 132.47, 132.17, 130.13, 130.07, 126.69, 126.16, 123.00, 120.83, 120.77, 110.34, 97.50, 69.23, 56.80, 40.08, 18.60, 18.13, 9.66. UPLC-MS (ESI): *m/z* = 472.2 (M+H)⁺.

2.8.20 6-Amino-4-(5-(((5-chloronaphthalen-1-yl)oxy)methyl)-2,4-dimethylphenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10t). The title compound was synthesized from 5-(((5-chloronaphthalen-1-yl)oxy)methyl)-2,4-dimethylbenzaldehyde (0.455 g) and 3-methyl-1*H*-pyrazol-5(4*H*)-one (0.137 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.468 g (71%). ¹H NMR (300 MHz, DMSO-*d*₆): δ = 12.10 (s, 1H, ArNH), 8.25–8.01 (m, 2H, ArH), 7.74–7.56 (m, 2H, ArH), 7.58 (d, *J* = 8.3 Hz, 2H, ArH), 7.25 (s, 1H, ArH), 7.07 (d, *J* = 8.4 Hz, 1H, ArH), 7.02 (s, 1H, ArH), 6.88 (s, 2H, ArNH₂), 5.19 (s, 2H, ArCH₂OAr), 4.86 (s, 1H, CHAr), 2.31 (s, 3H ArCH₃), 2.29 (s, 3H ArCH₃), 1.70 (s, 3H ArCH₃). ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 160.81, 155.21, 153.04, 135.31, 134.61, 134.57, 134.38, 132.65, 132.37, 130.44, 127.98, 126.62, 126.25, 126.13, 123.67, 122.08, 121.76, 120.91, 109.35, 106.29, 97.69, 68.25, 56.97, 18.55, 18.02 (two overlapping), 9.66. UPLC-MS (ESI): *m/z* = 471.2 (M+H)⁺.

2.8.21 6-Amino-4-(4-chlorophenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10u) [28]. The title compound was synthesized from 4-chlorobenzaldehyde (0.197 g) and 3-methyl-1*H*-pyrazol-5(4*H*)-one (0.137 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.301 g (75%). ¹H NMR (300 MHz, DMSO-*d*₆): δ = 12.13 (s, 1H, ArNH), 7.38 (d, *J* = 8.4 Hz, 2H, 2 × ArH), 7.19 (d, *J* = 8.5 Hz, 2H, 2 × ArH), 6.92 (s, 2H, ArNH₂), 4.63 (s, 1H, CHAr), 1.79 (s, 3H, ArCH₃); ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 160.90, 154.69, 143.49, 135.65, 131.21, 129.36, 128.45, 120.64, 97.19, 56.74, 35.55, 9.74. UPLC-MS (ESI): *m/z* = 287.1 (M+H)⁺.

2.8.22 6-Amino-3-methyl-4-(*o*-tolyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10v) [29]. The title compound was synthesized from 2-methylbenzaldehyde (0.168 g) and 3-methyl-1*H*-pyrazol-5(4*H*)-one (0.137 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.295 g (79%). ¹H NMR (300 MHz, DMSO-*d*₆): δ = 12.07 (s, 1H, ArNH), 7.18–7.06 (m, 3H, 3 × ArH), (dd, *J* = 7.7, 2.1 Hz, 1H, ArH), 6.82 (s, 2H, ArNH₂), 4.84 (s, 1H, CHAr), 2.28 (s, 3H, ArCH₃), 1.68 (s, 3H, ArCH₃); ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 160.74, 155.06, 141.86, 135.30, 134.95, 130.46, 128.88, 126.56, 126.30, 120.69, 97.53, 56.73, 33.07, 18.90, 9.52. UPLC-MS (ESI): *m/z* = 267.1 (M+H)⁺.

2.8.23 6-Amino-4-(2,4-dichlorophenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10x) [30]. The title compound was synthesized from 2,4-dichlorobenzaldehyde (0.243 g) and 3-methyl-1*H*-pyrazol-5(4*H*)-one (0.137 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.062 g (8%). ¹H NMR (300 MHz, DMSO-*d*₆): δ = 1.78 (s, 3H), 5.06 (s, 1H), 7.02 (s, 2H), 7.21 (d, 1H), 7.42 (d, 1H), 7.58 (s, 1H), 12.17 (s, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 9.60, 33.11, 38.69, 55.24, 96.38, 120.33, 128.08, 128.88, 132.16, 132.87, 135.49, 140.13, 154.93, 161.36. IR (neat): 1410, 1585, 2183, 3101, 3246. UPLC-MS (ESI): *m/z* = 321.0 (M+H)⁺.

2.8.24 6-Amino-4-(4-methoxy-2,3-dimethylphenyl)-3-methyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10y). The title compound was synthesized from 2,5-dimethylbenzaldehyde (0.188 g) and 3-methyl-1*H*-pyrazol-5(4*H*)-one (0.137 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.249 g (58%). ¹H NMR (300 MHz, DMSO-*d*₆): δ = 1.69 (s, 3H), 2.09 (s, 3H), 2.10 (s, 3H), 3.22 (s, 3H), 4.85 (s, 1H), 6.75–6.80 (m,

4H), 12.04 (s, 1H). ^{13}C NMR (75 MHz, DMSO- d_6): δ = 9.69, 10.06, 11.73, 12.01, 14.97, 16.50, 16.68, 30.75, 55.25, 55.53, 55.57, 57.61, 98.19, 99.82, 108.23, 108.37, 120.85, 123.71, 124.98, 125.09, 125.67, 127.24, 134.24, 134.85, 135.31, 154.98, 155.51, 156.90, 157.88, 160.56, 206.56. IR (neat): 1391, 1596, 2191, 3099, 3221. UPLC-MS (ESI): m/z = 311.1 (M+H) $^+$.

2.8.25 6-Amino-3-methyl-4-phenyl-1,4-dihydropyrano[2,3-*c*]pyrazole-5-carbonitrile (10z) [31]. The title compound was synthesized from benzaldehyde (0.149 g) and 3-methyl-1*H*-pyrazol-5(4*H*)-one (0.137 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.297 g (84%). ^1H NMR (300 MHz, DMSO- d_6): δ = 12.09 (s, 1H, ArNH), 7.31 (dd, J = 8.0, 6.8 Hz, 2H, ArH), 7.23 (d, J = 7.4 Hz, 1H, ArH), 7.20–7.13(m, 2H, ArH), 6.86 (s, 2H, ArNH $_2$), 4.59 (s, 1H, CHAr), 1.78 (s, 3H ArCH $_3$); ^{13}C NMR (75 MHz, DMSO- d_6): δ = 160.86, 154.76, 144.45, 135.55, 128.43, 127.46, 126.72, 120.79, 97.64, 57.17, 36.23, 9.74. UPLC-MS (ESI): m/z = 253.1 (M+H) $^+$.

2.8.26 6-Amino-4-(2,4-dimethylphenyl)-3-methyl-1,4-dihydropyrano[2,3-*c*]pyrazole-5-carbonitrile (10aa). The title compound was synthesized from 2,4-dimethylbenzaldehyde (0.188 g) and 3-methyl-1*H*-pyrazol-5(4*H*)-one (0.137 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.330 g (84%). ^1H NMR (300 MHz, DMSO- d_6): δ = 12.05 (s, 1H, ArNH), 6.93 (d, J = 2.3 Hz, 2H, ArH), 6.86 (d, J = 8.3 Hz, 1H, ArH), 6.79 (s, 2H, ArNH $_2$), 4.79 (s, 1H, CHAr), 2.24 (s, 3H ArCH $_3$), 2.23 (s, 3H ArCH $_3$), 1.69 (s, 3H ArCH $_3$); ^{13}C NMR (75 MHz, DMSO- d_6): δ = 160.65, 155.05, 135.40, 135.27 (two overlapping signals), 134.72, 131.11, 128.85, 126. UPLC-MS (ESI): m/z = 281.1 (M+H) $^+$.

2.8.27 6-Amino-4-(2,5-dimethylphenyl)-3-methyl-1,4-dihydropyrano[2,3-*c*]pyrazole-5-carbonitrile (10ab) [32]. The title compound was synthesized from 1,5-dimethylbenzaldehyde (0.188 g) and 3-methyl-1*H*-pyrazol-5(4*H*)-one (0.137 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.212 g (54%). ^1H NMR (300 MHz, DMSO- d_6): δ = 12.05 (s, 1H, ArNH), 7.01 (d, J = 7.7 Hz, 1H, ArH), 6.92 (dd, J = 7.8, 1.8 Hz, 1H, ArH), 6.81 (s, 2H, ArNH $_2$), 6.78 (s, 1H, ArH), 4.79 (s, 1H, CHAr), 2.24 (s, 3H ArCH $_3$), 2.19 (s, 3H ArCH $_3$), 1.69 (s, 3H ArCH $_3$); ^{13}C NMR (75 MHz, DMSO- d_6): δ = 160.71, 155.05, 135.30, 135.01, 131.86, 130.40, 129.19, 127.31 (two overlapping signals), 120.72, 97.59, 56.87, 20.67 (two overlapping signals), 18.52, 9.56. UPLC-MS (ESI): m/z = 281.1 (M+H) $^+$.

2.8.28 6-Amino-4-(4-fluorophenyl)-3-methyl-1,4-dihydropyrano[2,3-*c*]pyrazole-5-carbonitrile (10ac) [30]. The title compound was synthesized from 4-fluorobenzaldehyde (0.172 g) and 3-methyl-1*H*-pyrazol-5(4*H*)-one (0.137 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.249 g (58%). ^1H NMR (300 MHz, DMSO- d_6): δ = 1.79 (s, 3H), 4.64 (s, 1H), 6.92 (s, 2H), 7.10–7.30 (m, 4H), 12.13 (s, 1H). ^{13}C NMR (75 MHz, DMSO- d_6): δ = 9.78, 35.47, 38.69, 38.96, 39.24, 45.01, 49.29, 57.07, 97.53, 115.07, 115.36, 120.77, 129.33, 129.43, 135.67, 140.68, 140.72, 154.72, 159.37, 160.85. IR (neat): 1395, 1491, 1591, 2198, 3090, 3226. UPLC-MS (ESI): m/z = 271.1 (M+H) $^+$.

2.8.29 6-Amino-3-methyl-1,4-diphenyl-1,4-dihydropyrano[2,3-*c*]pyrazole-5-carbonitrile (10ad) [31]. The title compound was synthesized from benzaldehyde (0.149 g) and 1-phenyl-3-methyl-1*H*-pyrazol-5(4*H*)-one (0.244 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.069 g (15%). ^1H NMR (300 MHz, DMSO- d_6): δ = 7.82–7.75 (m, 2H, ArNH), 7.49 (dd, J = 8.5, 7.4 Hz, 2H, ArH), 7.39–7.29 (m, 4H, ArH), 7.29–7.23 (m, 4H, ArH), 7.20 (s, 2H, ArNH $_2$), 4.68 (s, 1H, CHAr), 1.78 (s, 3H ArCH $_3$); ^{13}C NMR (75 MHz, DMSO- d_6): δ = 159.41, 145.25, 143.87, 143.60, 137.52, 129.33, 128.52, 127.77, 127.04, 126.16, 120.00, 119.96, 98.63, 58.16, 36.73, 12.57. UPLC-MS (ESI): m/z = 329.1 (M+H) $^+$.

2.8.30 6-Amino-1-(4-chlorophenyl)-4-(2,5-dimethylphenyl)-3-methyl-1,4-dihydropyrano[2,3-*c*]pyrazole-5-carbonitrile (10ae). The title compound was synthesized from 2,5-dimethylbenzaldehyde (0.188 g) and 1-(4-chlorophenyl)-3-methyl-1*H*-pyrazol-5(4*H*)-one

(0.288 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.040 g (7%). M.p.: 166–168°C. ^1H NMR (300 MHz, DMSO- d_6): δ = 1.69 (s, 3H), 2.19 (s, 3H), 2.31 (s, 3H), 4.88 (s, 1H), 6.87 (s, 1H), 6.94 (d, 1H), 7.05 (d, 1H), 7.20 (s, 2H), 7.52 (d, 2H), 7.83 (d, 2H). ^{13}C NMR (75 MHz, DMSO- d_6): δ = 12.42, 18.63, 20.69, 49.30, 57.92, 99.00, 119.96, 121.25, 127.71, 129.28, 130.15, 130.41, 132.07, 135.39, 136.47, 140.88, 144.24, 145.70, 159.28. IR (neat): 1383, 1512, 1663, 2198, 3195, 3317, 3465. IR (neat): 1383, 1512, 1663, 2198, 3195, 3317, 3465. UPLC-MS (ESI): m/z = 391.1 (M+H) $^+$.

2.8.31 6-Amino-1-(4-chlorophenyl)-3-methyl-4-(o-tolyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10af). The title compound was synthesized from 2-methylbenzaldehyde (0.172 g) and 1-(4-chlorophenyl)-3-methyl-1H-pyrazol-5(4H)-one (0.288 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.015 g (3%). M.p.: 178°C. ^1H NMR (300 MHz, DMSO- d_6): δ = 1.69 (s, 3H), 2.37 (s, 3H), 4.94 (s, 1H), 7.09–7.22 (m, 6H), 7.53 (d, 2H), 7.83 (d, 2H). IR (neat): 1384, 1511, 1662, 2224, 3192, 3332, 3453. UPLC-MS (ESI): m/z = 377.1 (M+H) $^+$.

2.8.32 6-Amino-4-(2,4-dichlorophenyl)-3-methyl-1-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile (10ag) [32]. The title compound was synthesized from 2,4-dichlorobenzaldehyde (0.243 g) and 3-methyl-1-phenyl-1H-pyrazol-5(4H)-one (0.242 g) according to the general procedure. The product was isolated as a white powder. Yield: 0.047 g (8%). ^1H NMR (300 MHz, DMSO- d_6): δ = 1.78 (s, 3H), 5.15 (s, 1H), 7.24–7.55 (m, 7H), 7.61 (s, 1H), 7.77 (d, 2H). ^{13}C NMR (75 MHz, DMSO- d_6): δ = 12.37, 49.15, 49.23, 56.15, 97.31, 119.56, 120.06, 126.31, 128.13, 128.38, 128.98, 129.36, 132.50, 132.56, 133.09, 137.44, 139.28, 144.28, 144.84, 159.95. IR (neat): 1387, 1557, 2198, 3322, 3456. UPLC-MS (ESI): m/z = 399.1 (M+H) $^+$.

3. Competitive binding assays

IC₅₀ values for respective compounds were determined by competitive binding using time-resolved fluorescence resonance energy transfer (LanthaScreen, Invitrogen) on a Victor2 microplate reader (PerkinElmer). Briefly, a terbium labeled anti-GST antibody was used to label purified GST-tagged PPAR γ -LBD (ligand binding domain). Energy transfer from terbium to the tracer, a fluorescent pan PPAR agonist, enabled read-out of each test compounds' ability to displace the tracer. RFU values from dose-response curves (triplicate sampling) for test compounds as well as positive controls (rosiglitazone) were then analyzed using GraphPad Prism [33]. An unrestrained sigmoidal (one-binding site) dose-response curve was fitted to each data set by linear regression and allowing for determination of IC₅₀ values. All compounds were tested in 10 different concentrations ranging from 3 nM to 500 μM (rosiglitazone from 0.3 nM to 10 μM).

4. Nuclear receptor-LBD transactivation

Hepa 1–6 cells were grown in minimum essential medium (MEM) (Gibco) supplemented with 10% fetal calf serum (FCS) and antibiotics (62.5 $\mu\text{g}/\text{mL}$ penicillin and 100 $\mu\text{g}/\text{mL}$ streptomycin).

Mouse embryo fibroblasts (MEFs) were propagated in Dulbeccos Modified Eagle's Media (DMEM) supplemented with 10% FCS and antibiotics.

Cells (Hepa 1–6 were used for PPAR α whereas MEFs were used for PPAR γ , PPAR δ and RXR α transfections) were transfected in solution by Metafectene (Biontix) lipofection, essentially according to the manufacturer's instructions and seeded in media (MEM or DMEM supplemented with 10% fetal calf serum and antibiotics) in 96-well dishes at 24000 cells/cm². The transfection plasmid mix included the Gal4-responsive luciferase reporter, the expression vector for the fusion between the Gal4 DNA-binding domain and the nuclear receptor ligand binding domains, and a CMV-Renilla luciferase normalization vector (pRL-CMV, Promega).

Six hours after addition of transfection mix to the cells, the media was changed to media (MEM or DMEM) supplemented with vehicle (0.1% DMSO), positive control (1 μ M Rosiglitazone, 30 nM GW7647, 1 μ M L165041 or 0.2 μ M LG1069 for PPAR γ , PPAR α , PPAR δ and RXR α , respectively), or compound. Approx. 18 hours later, cells were harvested and lysates analyzed for Photinus and Renilla luciferase activity by luminometry. All data points were performed in at least triplicate and each sample measured in duplicate. Luminometer raw data was analyzed in Microsoft Excel spreadsheets and presented as column graphs depicting average values of triplicates and including standard deviations.

5. Multiple flexible alignment template

Evaluation of the dihydropyrano[2,3-*c*]pyrazoles **4**, **10a-10ah** PPAR γ binding modes was carried out using a multiple flexible alignment approach. The model was developed, refined and evaluated using the flexible alignment application of the MOE software. The agonist model set was generated using the SVL Batch FlexAlign script, based on a PDB compound set of eleven PPAR γ full agonists and twelve seven PPAR γ partial agonists. The set of model agonists was composed of known antidiabetic drugs, including Rosiglitazone (TZD) and Farglitazar (non-TZD) and other biological relevant agonist with either selective PPAR γ or dual PPAR- α/γ , PPAR- δ/γ selectivity; no pan PPAR agonists were included. The compound set employed in the development of the PPAR γ agonist binding model is given in [S2 File](#) in the Supporting Information. The binding model was then used for the virtual screening of the library of the dihydropyrano[2,3-*c*]pyrazoles (**4**, **10a-10ah**). To be a hit, the test ligand pose had to fit the defined threshold of the binding model ($\Delta G_{\text{intr}} = \Delta G - \Delta G_{\text{torsions}}$, i.e. the torsion scoring term was excluded) less negative than a threshold value of -10 kcal/mol passed the docking screen, and the remaining compounds were discarded.

Supporting information

S1 File. General Supporting Information.

(PDF)

S2 File. Model set of compounds for development of binding mode model.

(DOCX)

S3 File. Test set of compounds for validation of binding mode model.

(DOCX)

Acknowledgments

We thank the Danish Council for Independent Research, Natural Sciences, Technology and Production Sciences, DSF Center for Antimicrobial Research, Lundbeck Foundation, and Technical University of Denmark for financial support.

Author Contributions

Conceptualization: KQ MSS IK KK TEN.

Data curation: KQ RKP.

Methodology: JFJ MSS IK RKP KQ OT TEN.

Resources: TEN.

Software: OT IK MSS.

Supervision: KK IK KQ TEN.

Writing – original draft: KQ.

Writing – review & editing: KQ TEN RKP.

References

1. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. *J. Med. Chem.* 2000; 43(4): 527–550. PMID: [10691680](#)
2. Larsen TM, Toubro S, Astrup A. PPAR γ agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? *International Journal of Obesity* 2003; 27: 147–161. doi: [10.1038/sj.ijo.802223](#) PMID: [12586994](#)
3. Haslam E. *Shikimic Acid Metabolism and Metabolites*, John Wiley & Sons: New York, 1993.
4. Elte J, Blicklé J. Thiazolidinediones for the treatment of type 2 diabetes. *Eur. J. Intern. Med.* 2007; 18(1): 18–25. doi: [10.1016/j.ejim.2006.09.007](#) PMID: [17223037](#)
5. Guan Y, Hao C, Cha D, Rao R, Lu W, Kohan D, et al. Thiazolidinediones expand body fluid volume through PPAR γ stimulation of ENaC-mediated renal salt absorption. *Nat. Med.* 2005; 11: 861–866. doi: [10.1038/nm1278](#) PMID: [16007095](#)
6. Pan H, Lin Y, Chen Y, Vance D, Leiter E. Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: Relation to dysregulated phosphatidylcholine metabolism. *Vasc. Pharmacol.* 2006; 45(1): 65–71.
7. Henriksen K, Byrjalsen I, Qvist P, Beck-Nielsen H, Hansen G, Riis BJ, et al. Efficacy and safety of the PPAR γ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy. *Diabetes Metab. Res. Rev.* 2011; 27(4): 392–401. doi: [10.1002/dmrr.1187](#) PMID: [21328517](#)
8. Hwang J, Lee M, Kim H, Sung M, Kim H, Kim M, et al. Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR- γ signal pathways. *Phytother Res* 2008; 23(2): 262–266.
9. Kouskoumvekaki I, Petersen RK, Fratev F, Taboureau O, Nielsen TE, Oprea TI, et al. Discovery of a Novel Selective PPAR γ Ligand with Partial Agonist Binding Properties by Integrated in Silico/in Vitro Work Flow. *J. Chem. Inf. Model* 2013; 53(4): 923–937. doi: [10.1021/ci3006148](#) PMID: [23432662](#)
10. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. *Proc. Natl. Acad. Sci. U.S.A.* 2000; 97(13): 7124–7129. PMID: [10860979](#)
11. El-Tamany ES, El-Shahed FA, Mohamed BH. Synthesis and biological activity of some pyrazole derivatives. *J. Serb. Chem. Soc.* 1999; 64(1): 9–18.
12. Zaki MEA, Soliman HA, Hiekal OA, Rashad AE. Pyrazolopyranopyrimidines as a Class of Anti-Inflammatory Agents. *Z. Naturforsch. C* 2006; 61c: 1–5.
13. Sharanin YA, Sharanina LG, Puzanova VV. Nitrile cyclization reaction. VII. Synthesis of 6-amino-4-aryl-3-methyl-5-cyano-1H,4H-pyrazolo[3,4-b]pyrans. *Zh. Org. Khim.* 1983; 19(12): 2609–2615.
14. Gerish M, Krumper JR, Bergman RG, Don Tilley T. Rhodium(III) and Rhodium(II) Complexes of Novel Bis(oxazoline) Pincer Ligands. *Organometallics* 2003; 22(1): 47–58.
15. Wood JH, Tung CC, Perry MA, Gibson RE. The Sommelet Reaction in the Synthesis of Aromatic Dialdehydes¹. *J. Am. Chem. Soc.* 1950; 72(7): 2992–2993.
16. Esser B, Bandyopadhyay A, Rominger F, Gleiter R. From Metacyclophanes to Cyclacenes: Synthesis and Properties of [6.8]₃Cyclacene. *Chem. Eur. J.* 2009; 15(14): 3368–3379. doi: [10.1002/chem.200802297](#) PMID: [19280613](#)
17. Carpino LA. A New Synthesis of unsaturated acids. α,β -Acetylenic acids. *J. Am. Chem. Soc.* 1958; 80: 599–600.
18. Lehmann F, Holm M, Laufer S. Three-Component Combinatorial Synthesis of Novel Dihydroxyprano [2,3-c]pyrazoles. *J. Comb. Chem.* 2008; 10(3): 364–367. doi: [10.1021/cc800028m](#) PMID: [18407695](#)
19. Yuasa Y; Tsuruta H, Yuasa Y. Facile Synthesis of β -Keto Esters from Methyl Acetoacetate and Acid Chloride: The Barium Oxide/Methanol System. *Org. Process Res. Dev.* 1998; 2(6): 412–414.
20. Mendes E, Vernieres JC, Keane PE, Bachy A. *Eur. Patent EP A1 346208, 19891213, 1989.*
21. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR γ). *J. Biol. Chem.* 1995; 270(22): 12953–12956. PMID: [7768881](#)

22. Steindl TM, Schuster D, Laggner C, Langer T. Chemometric Analysis of Ligand Receptor Complementarity: Identifying Complementary Ligands Based on Receptor Information (CoLiBRI). *J. Chem. Inf. Model.* 2006; 46(2): 2146–2157.
23. Markt P, Schuster D, Kirchmair J, Laggner C, Langer T. Pharmacophore modeling and parallel screening for PPAR ligands. *J Comput. Aided. Mol. Des.* 2007; 21(10): 575–590.
24. Qvortrup K, Komnatny VV, Nielsen TE. A Photolabile Linker for the Solid-Phase Synthesis of Peptide Hydrazides and Heterocycles. *Org. Lett.* 2014; 16(18): 4782–4785. doi: [10.1021/ol502219s](https://doi.org/10.1021/ol502219s) PMID: [25166929](https://pubmed.ncbi.nlm.nih.gov/25166929/)
25. Zou Y, Hu Y, Liu H, Shi D-Q. An Efficient and Green Synthesis of 6-Amino-3-phenyl-4-aryl-1,4-dihydropyrano [2,3-c]pyrazole-5-carbonitrile Derivatives under Ultrasound Irradiation in Aqueous Medium. *J. Het. Chem.* 2013; 50(5): 1174–1179.
26. Gogoi S, Zhao C-G. Organocatalyzed enantioselective synthesis of 6-amino-5-cyanodihydropyrano [2,3-c]pyrazoles. *Tetrahedron Lett.* 2009; 50(19): 2252–2255. doi: [10.1016/j.tetlet.2009.02.210](https://doi.org/10.1016/j.tetlet.2009.02.210) PMID: [19915654](https://pubmed.ncbi.nlm.nih.gov/19915654/)
27. Harb AFA, Hesien AHM, Metwally SA, Elnagdi MH. The Reaction of Ethyl 6-Amino-5-cyano-4-aryl-2-methyl-4H-pyran-3-carboxylate with Nucleophilic Reagents. *Liebigs Annalen der Chemie* 1989; 6: 585–588.
28. Kshirsagar SW, Patil NR, Samant SD. Mg-Al Hydrotalcite as a First Heterogeneous Basic Catalyst for the Synthesis of 4H-Pyrano[2,3-c]pyrazoles Through a Four-Component Reaction. *Synth. Commun.* 2011; 41(9): 1320–1325.
29. Vasuki G, Kumaravel K. Rapid Four-Component Reactions in Water: Synthesis of Pyranopyrazoles. *Tetrahedron Lett.* 2008; 49(39): 5636–5638.
30. Abdou S, Fahmy SM, Sadek KU, Elnagdi MH. Activated Nitriles in Heterocyclic Synthesis: A Novel Synthesis of Pyrano[2,3-c]pyrazoles. *Heterocycles* 1981; 16(12): 2177–2180.
31. Kumar G, Santhosh KC, Veeraswamy B, Rao PS, Rao PS, Shanthan NB. An Efficient Multi-component Synthesis of 6-Amino-3-methyl-4-Aryl-2,4-dihydropyrano[2,3 c]Pyrazole-5-Carbonitriles. *Org. Prep. Proc. Int.* 2013; 45(5): 429–436.
32. Shi D, Mou J, Zhuang G, Niu L, Wu N, Wang X. Three-Component One-Pot Synthesis of 1,4-Dihydropyrano[2,3-c]pyrazole Derivatives in Aqueous Media. *Synth. Commun.* 2004; 34(24): 4557–4563.
33. GraphPad Software *GraphPad Prism*.